# A Study In Healthy Volunteers To Estimate The Pharmacokinetics Of Four Modified-Release Formulations Of Dimebon (Latrepirdine)

> **NCT00988624** · PHASE1 · COMPLETED · sponsor: **Pfizer** · enrollment: 20 (actual)

## Conditions studied

- Alzheimer's Disease
- Huntington Disease

## Interventions

- **DRUG:** Dimebon IR Tablet
- **DRUG:** Dimebon MR1
- **DRUG:** Dimebon MR2
- **DRUG:** Dimebon MR3
- **DRUG:** Dimebon MR4

## Key facts

- **NCT ID:** NCT00988624
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-10
- **Primary completion:** 2009-12
- **Final completion:** 2009-12
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2010-01-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00988624

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00988624, "A Study In Healthy Volunteers To Estimate The Pharmacokinetics Of Four Modified-Release Formulations Of Dimebon (Latrepirdine)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00988624. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*